ATI Advisory Appoints Anna Kaltenboeck To Lead New Drug Reimbursement Group

Back to Resources
ATINews
11/29/2022
AUTHOR – ATI Advisory

FOR IMMEDIATE RELEASE
ATI ADVISORY
11/29/22

WASHINGTON, Nov. 29, 2022 — ATI Advisory (ATI) welcomes Anna Kaltenboeck as Principal and Head of its Prescription Drug Reimbursement Group. Kaltenboeck brings proven experience from the public and private sectors, most recently as a Senior Health Advisor at the United States Senate’s Committee on Finance. Kaltenboeck’s focus there was on drug pricing and outpatient prescription drug coverage under Medicare Part D. ATI is a healthcare consulting firm dedicated to reducing complexity and costs to make care better for everyone, especially individuals with high needs.

“We are fortunate that Anna is joining our team,” said Anne Tumlinson, Founder and CEO of ATI Advisory. “Anna fits beautifully into ATI’s growing team of experts focused on innovative approaches to increasing access and value in healthcare, particularly for populations with high needs. Her leadership in shaping national reimbursement policy for prescription drugs and new health technologies, and her training in economics, make Anna ideally qualified to lead our drug pricing group.”

Before working on Capitol Hill, Kaltenboeck was the Senior Health Economist and Program Director for the Center for Health Policy and Outcomes and the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center. She developed and conducted research on policies to re-align payment for prescription drugs with evidence of their value and offer economic rewards for the creation of new treatments based on how much they improve patients’ lives.

“The call for new ways to pay for prescription drugs and health technologies is greater than ever. Getting it right requires careful attention to economic incentives throughout the healthcare system and understanding how to align those with the interests of patients, who need both affordability and innovation,” said Kaltenboeck. “I’m excited to join ATI because of their clear emphasis on health in our high need communities and their well-regarded, significant work that shapes policy discussions in support of our nation’s populations with complex care needs.” 

Anna Kaltenboeck has a bachelor’s and master’s degree in economics from Tufts University and a Master of Business Administration degree from Yale University. Kaltenboeck is a published author in numerous peer-reviewed journals, including the Annals of Internal Medicine and JAMA. As a sought-out expert and public speaker on prescription drug supply chain economics, reimbursement models, and value-based pricing. Her work has been featured in national media outlets, including Morning Consult, STAT News, and Health Affairs Blog.

ABOUT ATI ADVISORY:

ATI Advisory is a healthcare research and advisory services firm advancing innovation that fundamentally transforms the care experience for individuals, families, and communities. ATI guides public and private leaders in successfully scaling healthcare innovations. Its nationally recognized experts apply the highest standards in research and advisory services along with deep expertise to generate new ideas, solve hard problems, and reduce uncertainty in a rapidly changing healthcare landscape. For more information, visit www.atiadvisory.com.

MEDIA CONTACT:
Robert Shalett
Communications Director
robert@atiadvisory.com

Recent News

News

What The Inflation Reduction Act’s Reforms To Medicare Part D Mean For Prescription Drug Prices

Anna Kaltenboeck recently penned a Health Affairs article that explains how the Inflation Reduction Act will affect Medicare Part D and prescription drug pricing.
Read More Read More
News

More MA insurer audits mean more scrutiny on providers

Fred Bentley quoted in Modern Healthcare about considerations for providers with increased Medicare Advantage audits coming.
Read More Read More
News

CMS Proposal Marks Shift After Years of Skilled Nursing Frustration with Medicare Advantage Diversions

Fred Bentley talks to Skilled Nursing News transitions in care regarding skilled nursing and Medicare Advantage.
Read More Read More
Share
LinkedIn / /